Past Winners - Patient Care Enhancement Award

2019 award recipient 

Benzodiazepine and Sedative-Hypnotic Drug Use in Nova Scotia Hospitals: A Point Prevalence Survey

Heather L Neville, Mia Losier, Jennifer Pitman, Melissa Gehrig, Jennifer E Isenor, Laura V Minard, Ellen Penny, Susan K Bowles 

Nova Scotia Health Authority

Background: Benzodiazepines and sedative-hypnotic drugs (BZD/SHDs), such as zopiclone and the antidepressant trazodone, pose a number of risks such as falls, fractures, and confusion, especially in older adults. Use of these drugs is poorly understood in the acute care setting. 

Objectives: To determine the point prevalence and characterize use of BZD/SHDs in Nova Scotia hospitals with ≥ 30 acute care beds.

Methods: A point prevalence survey (PPS) was conducted by reviewing the health records of adults admitted to hospital between May and August 2016. The number of patients who received a BZD/SHD within the 24 hours prior to the start of the survey was divided by the total number of patients admitted to each ward to determine prevalence. Exclusions were patients < 18 years of age, drugs given by the intravenous route, and patients in long term care, mental health, addiction treatment, or critical care. Results were summarized descriptively.

Results: All 16 eligible hospitals participated in the PPS. The overall prevalence of BZD/SHD use was 34.6% (487/1409) and ranged from 15.6-56.3%. The average age of patients who received a BZD/SHD was 70.3 years, 30.8% of patients were ≥ 80 years of age, and 54.6% of patients were female. The most commonly used drugs included zopiclone (32.0%), lorazepam (21.9%), trazodone (21.9%) and clonazepam (11.3%). Top indications for use were bedtime/daytime sedation (60.0%) and anxiety (12.5%). In 17% of cases the indication could not be determined. Over half (55.7%) of the medications had been initiated at home and continued in hospital, the remainder were started in hospital (37.6%), or unknown (6.7%).

Conclusions: BZD/SHDs were frequently used by hospitalized patients in Nova Scotia. Areas identified for quality improvement included decreasing the use in older adults, preventing inappropriate initiation of BZD/SHDs in hospital, and improving the documentation of indications for BZD/SHD use.

Sponsored by Teva Canada Limited
 

Past award recipients

Abstracts for the projects listed below can be viewed in the Canadian Journal of Hospital Pharmacy (CJHP). Award-winning abstracts are generally published in the first or second issue of each volume.

2018

Sponsored by Teva Canada Limited

Shanna Trenaman 

A Cohort Study to Identify Risk Factors for Drug-Related Emergency Department Visits in Older Adults (completed at Nova Scotia Health Authority and Dalhousie University, Nova Scotia)

2017

Sponsored by Pfizer Canada Inc.

Melissa Gehrig, Susan Bowles

Ensuring Appropriate Use of Antipsychotic Medications in Older Patients with Dementia (completed at Nova Scotia Health Authority, Halifax, Nova Scotia)

2017

Sponsored by Teva Canada Limited

Janice K Yeung, Tim T Y Lau

Evaluation of Clostridium difficile Infection Management Policy with Clinical Pharmacy and Medical Microbiology Involvement at a Major Canadian Teaching Hospital (completed at Vancouver General Hospital, Vancouver, British Columbia)

2016

Sponsored by Pfizer Canada Inc.

Derek Jorgenson, Eric Landry, Jaris Swidrovich, Katherine Lysak

The Medication Assessment Centre: A Novel Student Training and Patient Care Program (completed at College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, Saskatchewan)

2016

Sponsored by Teva Canada Limited

Taryn Heck, Lauren Bresee, Sheri Koshman, Tania Mysak, Mary Gunther

Prescribing Patterns of Hospital Pharmacists with Additional Prescribing Authorization in Alberta (completed at University of Alberta Hospital, Edmonton, Alberta)

2015

Sponsored by Pfizer Canada Inc.

Shirin Abadi, Paul Koke, Susan Walisser, Winnie Cheng, Neil de Haan

Pharmacists' Interventions in New Ambulatory Chemotherapy Patients (completed at BC Cancer Agency, British Columbia)

2015

Sponsored by Teva Canada Limited

Anna Lee, Jennifer Harrison, Karen Chuk, Esther Fung

Implementation of an Outpatient Pharmacy Flu Vaccination Program for Solid Organ Transplant Patients (completed at University Health Network, Toronto, Ontario)

2014

Sponsored by Pfizer Canada Inc.

Peter Zed, Neil MacKinnon

Medication-Related Emergency Department Visits in Pediatrics: A Prospective Observational Study (completed at the IWK Health Centre, Halifax, Nova Scotia)

2014

Sponsored by Teva Canada Limited

Marie Danette Beechinor, Allan Mills

Risk Factors Associated with Venous Thromboembolic Disease in Orthopaedic Surgery Patients: A Retrospective Case Control Study for Quality Analysis (completed at the Credit Valley Hospital site of Trillium Health Partners, Mississauga, Ontario)

2013

Sponsored by Teva Canada Limited

Katherine Lang, Kaitlyn McMillan, Allison Marcil, Lynette Kosar, Lisa Ruda, Zack Dumont

Analysis of Opioid Incidents Requiring Naloxone Administration (completed at Regina Qu'Appelle Health Region, Regina, Saskatchewan)

2012

Sponsored by AstraZeneca Canada Inc.

Derek Jorgenson, Anne Marie Whelan

Evaluating the Role of Pharmacist Teachers in Canadian Family Medicine Residency Programs: A Qualitative Analysis (completed at West Winds Primary Health Centre, Saskatoon, Saskatchewan)

2012

Sponsored by Teva Canada Limited

Danica Irwin, Régis Vaillancourt

Development and Implementation of a Pediatric Emergency Department (ED) Asthma Action Plan and Prescription (AAPP) (completed at the Children’s Hospital of Eastern Ontario, Ottawa, Ontario)

2011

Sponsored by AstraZeneca Canada Inc.

Jennifer Chen, Sabrina Boodhan, Sara Rosaline Lavoratore, L Lee Dupuis

A Reliable Method of Obtaining Blood Samples from Implantable Central Venous Catheters for Determination of Plasma Gentamicin Concentrations (completed at The Hospital for Sick Children, Toronto, Ontario)

2011

Sponsored by Teva Canada Limited

Sayako Yokoyama, Damen Man, Vincent Mabasa

An Analysis of QTc Prolonging Medication Orders Belonging to Intensive and Cardiac Care Unit Patients with Pre-existing QTc Prolongation (QTIPPP Study) (completed at Burnaby Hospital, Burnaby, British Columbia)

2010

Sponsored by AstraZeneca Canada Inc.

Régis Vaillancourt

Administration of 24% Sucrose for Procedural Pain Management in Neonates: An Evidence-Based Approach to Changing Practice (completed at the Children’s Hospital of Eastern Ontario, Ottawa, Ontario)

2010

Sponsored by Teva Novopharm

Angela McKinnon, Derek Jorgenson

Pharmacist and Physician Collaborative Prescribing for Medication Renewals within a Primary Health Centre (completed at West Winds Primary Health Centre, Saskatoon, Saskatchewan)

2009

Sponsored by AstraZeneca Canada Inc.

Robert M Balen, Peter S Loewen, Matthew O Wiens, Kerry Wilbur, Peter J Zed

Clinical Pharmacy Support Technicians: Increasing Pharmaceutical Care Practice Efficiency in the Intensive Care Unit Setting (completed at Royal Columbian Hospital, New Westminster, British Columbia)

2009

Sponsored by Hospira Healthcare Corporation

Sheri Koshman, Mark Makowsky, Ross Tsuyuki

Capturing Outcomes of Clinical Activities Performed by a Rounding Pharmacist Practicing in a Team Environment (completed at Royal Columbian Hospital, New Westminster, British Columbia)

Inquiries should be directed to :

Robyn Rockwell, Membership & Awards Administrator
awards@cshp.pharmacy
Toll Free: 1 (877) 340-2756, ext. 222
Direct: (613) 736-9733, ext. 222